Houslay MD[au] - Search Results

Year	Number of Results
1973	3
1974	2
1975	5
1976	5
1977	8
1978	6
1979	5
1980	11
1981	7
1982	7
1983	15
1984	10
1985	4
1986	10
1987	11
1988	10
1989	19
1990	12
1991	9
1992	5
1993	9
1994	9
1995	12
1996	10
1997	16
1998	11
1999	6
2000	8
2001	11
2002	8
2003	8
2004	6
2005	13
2006	16
2007	15
2008	11
2009	11
2010	23
2011	16
2012	1
2013	3
2014	7
2015	6
2016	7
2017	4
2018	4
2019	5
2020	1
2022	2

1

Withdrawal: Mdm2 directs the ubiquitination of β-arrestin-sequestered cAMP phosphodiesterase-4D5.

Li X, Baillie GS, Houslay MD. Li X, et al. Among authors: houslay md. J Biol Chem. 2020 Aug 21;295(34):12328. doi: 10.1074/jbc.W120.015374. J Biol Chem. 2020. PMID: 32826336 Free PMC article. No abstract available.

2

PDE4 cAMP-specific phosphodiesterases.

Houslay MD. Houslay MD. Prog Nucleic Acid Res Mol Biol. 2001;69:249-315. doi: 10.1016/s0079-6603(01)69049-4. Prog Nucleic Acid Res Mol Biol. 2001. PMID: 11550796 Review. No abstract available.

3

A RSK(y) relationship with promiscuous PKA.

Houslay MD. Houslay MD. Sci STKE. 2006 Aug 22;2006(349):pe32. doi: 10.1126/stke.3492006pe32. Sci STKE. 2006. PMID: 16926362 Review.

4

Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown.

Houslay MD. Houslay MD. Trends Biochem Sci. 2010 Feb;35(2):91-100. doi: 10.1016/j.tibs.2009.09.007. Epub 2009 Oct 26. Trends Biochem Sci. 2010. PMID: 19864144 Review.

5

Tailoring cAMP-signalling responses through isoform multiplicity.

Houslay MD, Milligan G. Houslay MD, et al. Trends Biochem Sci. 1997 Jun;22(6):217-24. doi: 10.1016/s0968-0004(97)01050-5. Trends Biochem Sci. 1997. PMID: 9204709 Review.

6

Keynote review: phosphodiesterase-4 as a therapeutic target.

Houslay MD, Schafer P, Zhang KY. Houslay MD, et al. Drug Discov Today. 2005 Nov 15;10(22):1503-19. doi: 10.1016/S1359-6446(05)03622-6. Drug Discov Today. 2005. PMID: 16257373 Review.

7

Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action.

Francis SH, Houslay MD, Conti M. Francis SH, et al. Among authors: houslay md. Handb Exp Pharmacol. 2011;(204):47-84. doi: 10.1007/978-3-642-17969-3_2. Handb Exp Pharmacol. 2011. PMID: 21695635 Review.

8

Molecular basis of insulin receptor function.

Houslay MD, Siddle K. Houslay MD, et al. Br Med Bull. 1989 Jan;45(1):264-84. doi: 10.1093/oxfordjournals.bmb.a072316. Br Med Bull. 1989. PMID: 2507087 Review.

9

FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system.

Yalla K, Elliott C, Day JP, Findlay J, Barratt S, Hughes ZA, Wilson L, Whiteley E, Popiolek M, Li Y, Dunlop J, Killick R, Adams DR, Brandon NJ, Houslay MD, Hao B, Baillie GS. Yalla K, et al. Among authors: houslay md. Mol Psychiatry. 2018 May;23(5):1278-1286. doi: 10.1038/mp.2017.138. Epub 2017 Jul 20. Mol Psychiatry. 2018. PMID: 28727686 Free PMC article.

10

Arresting times for PTEN.

Houslay MD. Houslay MD. EMBO J. 2011 Jul 6;30(13):2513-5. doi: 10.1038/emboj.2011.200. EMBO J. 2011. PMID: 21731046 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results